Surprisingly, neither survival correlations nor the analysis of CDK8/CDK19/CCNC gene alterations or expression provided any rationale for using CDK8/19 inhibitors to target acute myeloid leukemia (AML), the only disease where a subset of cell lines was found to be highly susceptible to anti-proliferative effects of CDK8/19 inhibition [11,12]. The gene discussed is CDK8; the disease is acute myeloid leukemia.